Navigation Links
Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
Date:2/10/2008

- Dr. Benjamin Ascher, a Leading French Plastic Surgeon, Will Present his UltraShape Clinical Results at the International Society of Aesthetic

Plastic Surgery Meeting in Melbourne, AU From Feb. 10-13

YOQNEAM, Israel and SAN RAMON, Calif., Feb. 10 /PRNewswire/ -- Renowned French Plastic Surgeon, Dr. Benjamin Ascher will present his latest findings from clinical experience with UltraShape(TM) Contour I at the 19th annual International Society of Aesthetic Plastic Surgery (ISAPS) meeting to be held in Melbourne, Australia from February 10-13. UltraShape is the clinically proven non-invasive solution for fat reduction and body contouring using "non- thermal" selective focused ultrasound technology.

Dr. Benjamin Ascher of the Clinique of Aesthetic Surgery IENA in Paris, France, and Course Director the IMCAS Congresses (International Master Course on Aging Skin and Aesthetic Surgery), will present his two most recent clinical trials. The first clinical trial (carried out from January through October 2006) involved 130 patients. Results demonstrated that following a three-treatment protocol using the UltraShape Contour I system, 92% of patients experienced a measurable reduction in body circumference and 88% of patients expressed satisfaction with their results. The second trial (conducted from October 2006 through January 2007 on 24 patients) follows a three-treatment protocol, with shortened intervals between treatments, and has demonstrated preliminary results of successful mean circumferential reduction of 3.54 cm after only two treatments. Dr. Ascher commented, "My patients have been extremely satisfied with the pain-free, 'walk-in, walk out' nature of UltraShape procedure and the long-lasting fat reduction and body contouring effects. As an Aesthetic Surgeon, I am pleased both with the results my patients have experienced from UltraShape's innovative technology and the role that it has played as a growth engine for my clinic."

As part of the ISAPS on-going efforts to provide physicians with the latest information and access to innovative procedures, Robert Gerberich, President of UltraShape Americas & APAC will review the UltraShape technology and the extensive scientific research and published clinical studies supporting its' safety and efficacy, and Ido Frank, UltraShape's Clinical Applications Specialist, will provide a live demonstration and hands-on workshop.

Rodger Stewart, UltraShape President and CEO stated, "UltraShape is honored to contribute to the ISAPS initiative of uniting physicians with the latest and most innovative technology in medical aesthetics. The positive results of the independent study, by such a renowned plastic surgeon as Dr. Benjamin Ascher, confirm UltraShape's safety and effectiveness. Physicians working with UltraShape around the world have seen positive results in their patients and a successful impact on their clinics."

About ISAPS

The International Society of Aesthetic Plastic Surgery (ISAPS) is the world's leading professional body for board certified aesthetic plastic surgeons. The Society was founded to provide a forum for, "The interchange of ideas and knowledge for the advancement of aesthetic plastic surgery." In addition, ISAPS has become the gold standard for providing continuing education to its members in new procedures, techniques and options in aesthetic and reconstructive plastic surgery.

ISAPS membership is drawn from over 1,300 of the world's best known and respected reconstructive and aesthetic plastic surgeons in 73 countries on every continent. Reflecting the true international mission of the organization, ISAPS' charter was signed at the United Nations. For more information, please visit http://www.isaps.org

About the UltraShape CONTOUR I

The UltraShape Contour I system, based on patented focused ultrasound technology, is the first scientifically and clinically proven non-invasive fat reduction and body contouring solution for both men and women. The device produces mechanical, non-thermal, acoustic effects which targets and selectively destroys fat cells, leaving surrounding critical structures such as skin, blood vessels, nerves, and connective tissue intact. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software guarantees adherence to a pre-determined treatment algorithm minimizing risk of contour irregularities, a common side effect of liposuction. The UltraShape procedure is performed during a convenient, "walk-in, walk-out" session carried out in an office-based environment; it requires no anesthesia or sedation, and the vast majority of patients report no pain or discomfort. After treatment, patients immediately resume their daily routines with no need for maintenance treatments. The UltraShape procedure is available in 50 countries and over 50,000 patient treatments have been performed worldwide with high patient satisfaction. The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The UltraShape Contour I system is not available for sale in the United States.

About UltraShape

UltraShape is redefining aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for body contouring. The company is dedicated to providing clinically proven safe and effective solutions that enhance the lives of patients worldwide. The UltraShape proprietary non-invasive body contouring technology is based on focused ultrasound that targets and selectively disrupts fat cells without affecting surrounding structures. Founded in 2000, UltraShape is a privately held and venture backed company. For more information visit http://www.ultrashape.com.

Abigail Marks

UltraShape

+972-4-909-4029

abigail@ultrashape.com

Paula Moggio

FischerHealth

+1-310-577-7870 x151

pmoggio@fischerhealth.com

Jessica Fishman

Gitam Porter Novelli

+972-3-576-5798

jessica@gitam.co.il


'/>"/>
SOURCE UltraShape Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
2. Video: New Research Discovers Independent Brain Networks Control Human Walking
3. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
4. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
5. IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients
6. Rapid Growth of Asia-Pacific Clinical Trials Market Focus of New CenterWatch Report
7. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
8. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
11. Successful Clinical Trials and Launch in New Zealand Spurs Phloe to Enter US Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) ... of reducing expression of Ki67, a biomarker of cell ... the Phase 2 trial presented during the official press ... (SABCS) evaluated abemaciclib, both alone or in combination with ...
(Date:12/7/2016)... Global Cervical Dysplasia Market: Scope and ... dysplasia market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/7/2016)... REPORT OBJECTIVES The report ... intelligence on a market segment, based on geography. ... in the report. The primary objectives of this ... intelligence through detailed segmentation, 2) market size and ... developments, market situation, trends, 3) detailed analysis of ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand marijuana ... the Icahn School of Medicine at Mount Sinai has found. The study was ... children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite of ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, ... Device Remote Control through a new partnership with Splashtop Inc. This remote control ... mobile solutions to help businesses maximize their uptime and productivity. , Wavelink offers ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... S.L. (“Presence”) for a purchase price of approximately $17.4 million (net of ... annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is ...
(Date:12/7/2016)... Yorba Linda, Ca (PRWEB) , ... December 07, 2016 , ... ... to attain that funding is with useful, properly analyzed data. The team at Beckman ... generation to address the 'need for speed' and the need to operate in a ...
(Date:12/7/2016)... ... 2016 , ... A quote from Dr. Edward Hallowell, host of CRN International’s ... offer a rare glimpse into the mind of those people with ADHD. , Dr. ... author, has described people with ADHD as having “Ferrari engines for a brain, with ...
Breaking Medicine News(10 mins):